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The role of short chain fatty acids in appetite regulation and
energy homeostasis
CS Byrne1, ES Chambers1, DJ Morrison2 and G Frost1
Over the last 20 years there has been an increasing interest in the inﬂuence of the gastrointestinal tract on appetite regulation.
Much of the focus has been on the neuronal and hormonal relationship between the gastrointestinal tract and the brain. There is
now mounting evidence that the colonic microbiota and their metabolic activity have a signiﬁcant role in energy homeostasis. The
supply of substrate to the colonic microbiota has a major impact on the microbial population and the metabolites they produce,
particularly short chain fatty acids (SCFAs). SCFAs are produced when non-digestible carbohydrates, namely dietary ﬁbres and
resistant starch, undergo fermentation by the colonic microbiota. Both the consumption of fermentable carbohydrates and the
administration of SCFAs have been reported to result in a wide range of health beneﬁts including improvements in body
composition, glucose homeostasis, blood lipid proﬁles and reduced body weight and colon cancer risk. However, published studies
tend to report the effects that fermentable carbohydrates and SCFAs have on speciﬁc tissues and metabolic processes, and fail to
explain how these local effects translate into systemic effects and the mitigation of disease risk. Moreover, studies tend to
investigate SCFAs collectively and neglect to report the effects associated with individual SCFAs. Here, we bring together the recent
evidence and suggest an overarching model for the effects of SCFAs on one of their beneﬁcial aspects: appetite regulation and
energy homeostasis.
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INTRODUCTION
Obesity has become a global epidemic, with incidence rates of
over 20% in the majority of western countries.1 It has been
proposed that the current obesity epidemic may have been
caused by a mismatch between the physiological mechanisms for
maintaining energy balance, which evolved in response to
ancestral diets, and the composition of the current western
diet.2 Over the past several decades, the western diet has changed
signiﬁcantly with the popularity of ‘fast’ and ‘convenience’ foods
rapidly increasing.3 Such foods are energy dense, have a low
dietary ﬁbre content and produce lower satiety and satiation
signals than low-energy dense foods.4 This diet is markedly
different to the historical low-energy dense, nutrient-poor diet
that the human gut was adapted to over several millennia.
Evidence suggests that for most of history the human lineage
consumed more indigestible plant material, such as grasses,
sedges and tubers, than is present in a typical western-style diet
(4100 g per day dietary ﬁbre compared with o15 g per day in
the average modern-day diet), and is therefore likely to have
contained a larger non-digestible component.5,6
Some carbohydrates resist digestion in the upper gastrointest-
inal tract and reach the large bowel mainly intact where they are
subject to fermentation by the resident bacteria. The human gut
microbiota is composed of 1013 –1014 microorganisms, accounting
for 41 kg of body weight.7,8 The gut microbiota is continuing to
emerge as a major determinant of obesity and its associated
health complications.9,10 However, as this topic is beyond the
scope of the present review readers are referred to the excellent
review by Holmes et al.11, which focuses on the composition and
functional activities of the gut microbiota.
The principle products of the bacterial fermentation of non-
digestible carbohydrates in the gut are short chain fatty acids
(SCFAs), heat and gases.12–14 The process of bacterial fermentation
serves as an energy harvest system for undigested material,
rescuing energy that cannot be absorbed in the small bowel, and
is used as a major energy source for some species. For example,
lowland gorillas derive ~ 57% of their metabolisable energy from
SCFAs, compared with 1.2–10% in humans from the average
western diet.15–17 The main SCFAs produced by bacterial
fermentation are acetate, propionate and butyrate, and are
present in the approximate molar ratio of 60:20:20.18 It has been
demonstrated that the consumption of soluble fermentable
carbohydrates (FCs) increases the caecel content of SCFAs in
animal models.19,20 The rate, ratio and extent of SCFA production,
however, is a complex interplay between FC type, microbiome
diversity and activity, and gut transit time.21–25
Supplementing the high-fat diet of rodents with soluble FCs has
been shown to protect against body weight and fat mass
gain.26–28 Futhermore, research suggests that adult rodents who
consume a weaning diet high in prebiotic ﬁbre are protected
against body weight gain when challenged with a western-style
diet high in fat and sucrose.29 However, research carried out
by Track et al.30 suggests that the beneﬁcial effects of FC
consumption are speciﬁc to adolescent rodents. In addition to
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improvements in body composition, a number of research studies
in humans have reported associations between the consumption
of FCs and improvements in glucose homeostasis, insulin
sensitivity and blood lipid proﬁles, however, these beneﬁcial
effects were not present in young healthy adults.31–36
Although it is known that greater FC consumption increases
colonic SCFA production resulting in a wide range of health
beneﬁts, further research is needed to fully elucidate the
molecular mechanisms by which SCFA mediate these effects.
Published research often focuses on single mechanisms to explain
the positive physiological effects associated with gut-derived
SCFAs. However, we hypothesise that the beneﬁcial effects
reported are not the result of the activity of a single metabolic
process on a speciﬁc tissue, but are more likely to be the result of
the stimulation of a number of mechanisms activated in parallel.
Here we review recent ﬁndings in this ﬁeld and propose an
interconnected picture of how SCFAs may affect appetite
regulation and energy homeostasis.
MATERIALS AND METHODS
A review of the literature was conducted in 2014 using PubMed
databases, with the following search terms: ‘short chain fatty acids’
AND dietary ﬁber(MeSH terms), ‘short chain fatty acids’ AND
obesity(MeSH terms), ‘short chain fatty acids’ AND appetite(MeSH
terms), ‘short chain fatty acids’ AND energy intake(MeSH terms),
‘short chain fatty acids’ AND energy expenditure(MeSH terms),
‘short chain fatty acids’ AND microbiota(MeSH terms), ‘short chain
fatty acids’ AND (‘free fatty acid receptor 3’ OR ‘GPR41’ OR
‘GPCR41’) and ‘short chain fatty acids’ AND (‘free fatty acid
receptor 2’ OR ‘GPR43’ OR ‘GPCR43’). Reviews and research studies
in which immune function or cancer progression/prevention were
the primary focus were excluded as these topics were deemed
beyond the scope of this review. Papers identiﬁed from the search
were analysed by two of the authors and papers that were not
relevant were rejected as shown in Figure 1. In total, 104 papers
were identiﬁed as containing relevant primary evidence.
SCFAs and free fatty acid receptor signalling
In 2003, three independent research groups discovered that the
orphan G-protein-coupled receptors, GPR43 and GPR41, were
activated by SCFAs.37–39 These receptors have since been
renamed free fatty acid receptor 2 and 3 (FFA2 and FFA3; formerly
GPR43 and GPR41, respectively). Acetate and propionate are the
most potent activators of FFA2, whereas FFA3 is activated in the
afﬁnity order propionate4butyrate⩾ acetate.37–39 However,
results of studies using animal models must be noted with
caution owing to interspecies variability. Hudson et al.40 reported
that in mice FFA2 and FFA3 have equal afﬁnity for acetate and
butyrate, whereas FFA3 has higher afﬁnity for propionate
than FFA2.
FFA2 and FFA3 are both widely expressed throughout the small
intestine and colon.37,41,42 FFA2 and FFA3 mRNA have also been
discovered in areas other than the gut, which lead to the
assumption that SCFAs are likely to have beneﬁcial effects on
tissues and organs beyond the gut. FFA2 mRNA has been
detected in immune cells, skeletal muscle, heart, spleen and
adipose tissue,37,42–44 whereas the expression of FFA3 appears to
be more widespread and has been detected in adipose tissue,
peripheral blood mononuclear cells, pancreas, spleen, bone
marrow and lymph nodes.37,38,42 However, reports investigating
the expression of both SCFA receptors in adipose tissue have
proven to be inconsistent.37,43,45–47
SCFAs and energy intake in animal models
The addition of FCs to the diets of animals has been shown to
reduce energy intake.26,27,48,49 Several studies have investigated
the effect of FCs on feeding motivation, however, the results have
been equivocal.50,51 Results from studies published by our
research group have shown that FCs increase manganese-
enhanced magnetic resonance imaging signals in the appetite
centres of the hypothalamus, further suggesting a satiating
effect.52,53 In addition, feeding FCs, as well as SCFAs themselves,
have been associated with an increase in the circulating
concentrations of the anorectic gut hormones, glucagon-like
peptide-1 (GLP-1) and peptide YY (PYY).26,27,29,48,54–59 GLP-1 and
PYY are produced by L cells, which are present throughout the
gastrointestinal tract, with the highest concentrations observed in
the distal ileum and colon, and are released in response to food
intake.60,61 Peripheral infusions of these gut hormones have been
shown to cause a reduction in energy intake and have thus
become the target of many anti-obesity therapies.62–65
The discovery of the co-expression of FFA2 and FFA3 in GLP-1
and PYY releasing enteroendocrine L cells has prompted
suggestions that the detection of SCFAs in the colon may
be responsible for triggering the release of these gut
hormones.54,66,67 This theory is supported by reports that FFA3
knock-out (KO) mice demonstrate an impaired PYY expression68
and that FFA2 KO mice exhibit reduced GLP-1 concentrations
in vivo and in response to SCFA in vitro.54 Furthermore, FC
supplementation has been shown to increase the densities of
FFA2-positive enteroendocrine cells in parallel with GLP-1-
containing cells.69 However, it is currently unclear whether this
is because of a SCFA-stimulated increase in cell proliferation or an
increase in the expression of SCFA receptors in the gut epithelium.
It has recently been reported that propionate stimulates the
secretion of both GLP-1 and PYY from wild type (WT) primary
murine colonic crypt cultures, an effect that was signiﬁcantly
reduced in FFA2 KO mice cultures.70 In addition, intra-colonic
infusions of propionate reportedly increased both GLP-1 and PYY
levels in jugular vein plasma in vivo, an effect that was not present
in FFA2 KO mice. These data further support the mounting
evidence that FCs stimulate the secretion of GLP-1 and PYY.
Additional evidence suggests a role for propionate in the
modulated expression of FFA2, PPAR-γ (peroxisome proliferator-
activated receptor gamma), Fiaf and histone deacetylases.71
Our research group recently investigated the role of the most
abundant SCFA, acetate, in central appetite regulation in mice.72 In
line with recent observations, we noted that dietary supplementa-
tion with the FC inulin causes a signiﬁcant reduction in energy
intake and weight gain.26,73 In addition, we investigated the effect
Figure 1. Flowchart outlining the methods used for research
paper selection.
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of intravenous and colonic infusions of 11C-acetate in vivo using
positron-emission tomography-computed tomography scanning
and found that although the majority of 11C-acetate tracer was
absorbed by the heart and liver, a small amount crossed the
blood-brain barrier (~3%) and was taken up by the brain. We
subsequently conﬁrmed that acetate induces hypothalamic
neuronal activation in the arcuate nucleus following intraperito-
neal administration, suggesting that acetate itself is an anorectic
signal.
That FCs reportedly have beneﬁcial effects on energy home-
ostasis but also increase energy harvest appears counterintuitive.
It has been suggested that the metabolisable energy gained from
SCFAs via the colonic fermentation process of non-digestible
carbohydrates may outweigh the beneﬁcial effects associated
with their consumption. Indeed, Isken et al.74 demonstrated that
long-term consumption (45 weeks) of soluble guar ﬁbre sig-
niﬁcantly increased both body weight and markers of insulin
resistance in mice, when compared with controls, despite a
comparable dietary energy intake in both groups. Their data
provides evidence that increased SCFA production in rodents,
which signiﬁcantly contributes to digested energy, may outweigh
the short-term beneﬁcial effects of soluble ﬁbre consumption.
These results may be explained by research carried out by Track
et al.30, which reported that feeding adolescent rats guar gum
results in a reduction in food intake and weight gain and
improved glucose tolerance. However, these beneﬁcial effects
were only observed in adolescent rats, when compared with
controls, and were absent in adults.
FCs and energy intake in humans
As discussed earlier, evidence suggests that hominin’s diets
consisted of mainly vegetable matter and would have had a large
fermentable component.5 It is highly likely that this large FC
consumption would therefore have stimulated gut hormone
release, slowing gastric emptying and small intestinal transit. It
is possible that this was advantageous as it would have increased
the energy harvest from nutritionally poor food during periods
when it was a major struggle for hominins to meet their energy
demands. However, it is likely that this physiological adaptation is
underutilised by humans in the developed world owing to wider
food availability and the lower FC content of the average
westerner’s diet.15 Behall et al.75 suggest that the fermentation
process signiﬁcantly contributes to digestible energy when
amounts of 420 g non-digestible carbohydrates are consumed.
It has been demonstrated that overweight and obese individuals
have higher faecal SCFA concentrations than their lean
counterparts.24,76 The results suggest that these individuals
produce more colonic SCFA, indicating an increased microbial
energy harvest in obesity.76 However, in vitro fermentations using
faecal samples from obese and lean individuals displayed no
difference in total SCFA production.77
Although there is clear evidence from a number of small animal
studies that the addition of FCs to the feed of high-fat-fed animals
results in improvements in body weight and composition,26–28
translation to humans has proven inconsistent. This may be owing
to the relatively small amount of FC used in human experimental
diets compared with animal studies (1.5% and 45% of total
energy intake, respectively). Large amounts of FCs are generally
not well tolerated as they are associated with undesirable
gastrointestinal effects, resulting in the use of lower doses in
human research trials.
However, a number of notable acute and long-term supple-
mentation studies have been successfully carried out in humans.
Archer et al.78 reported that replacing fat with an acute dose of
inulin (24 g) at breakfast results in lower energy and fat intake
throughout the day, although gut hormone concentrations were
not reported. Nilsson et al.79 demonstrated that consuming an
evening meal consisting of FCs signiﬁcantly increases circulating
PYY concentrations and decreases ghrelin concentrations at
breakfast. Our research group recently carried out a dose-ﬁnding
study and demonstrated that increased circulating PYY concen-
trations and appetite suppression occurs only with an acute dose
of435 g per day of inulin, suggesting the need for large doses in
order to induce appetite suppression.80 Evidence from long-term
studies suggest that supplementation (2–12 weeks) with oligo-
fructose (16–30 g per day) signiﬁcantly increases feelings of satiety
and reduces feelings of hunger, reduces energy intake, increases
the total area under the curve for PYY and reduces total area
under the curve for ghrelin, an orexigenic hormone.81–83 A 1-year
study investigating supplementation with high-wheat ﬁbre also
resulted in both an increase in SCFA production and GLP-1
secretion.84 The authors note that these changes took
9–12 months to develop, suggesting that it may take up to a
year for the gut microbiota to adapt to the extra fermentable
content of the diet. However, data from a recent study showed
that short-term dietary change alters both the microbial commu-
nity structure and gene expression of the human gut microbiome,
rapidly and reproducibly.85 Thus, the optimum time period for
adaptation to a high FC diet is, at the present time, unclear.
Our research group recently investigated the role of propionate
in appetite regulation. We demonstrated that propionate sig-
niﬁcantly stimulates the release of PYY and GLP-1 from human
colonic cells.86 Next, we produced a novel system, inulin-
propionate ester, whereby propionate is conjugated by an ester
linkage to inulin, a carrier molecule. The ester linkage is broken
down by bacterial fermentation, which results in the delivery of
propionate directly to the colon. When administered acutely, we
found that inulin-propionate ester signiﬁcantly increased post-
prandial PYY and GLP-1, and reduced energy intake by ~ 14% at a
buffet meal. Furthermore, after a 24-week supplementation period
we demonstrated that inulin-propionate ester signiﬁcantly
reduced weight gain in overweight adults.
Beneﬁcial effects associated with SCFA production independent of
food intake
The importance of SCFAs to energy metabolism has been further
emphasised in recent studies where germ-free mice have received
gut microbiota transplants. These investigations highlight that the
transfer of gut microbiota compositions, which produce different
levels of SCFAs in the colon, inﬂuence body weight gain and
adiposity.87,88 For example, it has been shown that the
transplantation of the faecal microbiota of twins discordant for
obesity to germ-free mice results in a similar phenotype in the
recipient mice.87 It was noted that the lean mice demonstrated
signiﬁcantly increased caecal propionate and butyrate contents
when compared with their obese counterparts. Their data suggest
that the increased weight gain observed in the obese mice was
not caused by an increased energy harvest by the gut microbiota
and suggests that instead, SCFAs inhibit the fat accumulation
associated with obesity. Similarly, the faecal transplantation of
mice that have undergone Roux-en-Y gastric bypass (RYGB)
surgery to germ-free mice has been shown to result in weight loss
and reduced fat mass in the RYGB-recipient mice.88 In addition,
the RYGB-recipient mice exhibited a relatively greater production
of propionate and lower production of acetate when compared
with mice that received the faecal microbiota of those that had
undergone sham surgery. The beneﬁcial change in body
composition observed in RYGB-recipient mice may be owing to
the beneﬁcial effects associated with the SCFA production proﬁle
of these mice. The authors suggest that the reduced levels of
acetate would result in decreased lipogenesis and that the
increased levels of propionate would assist in the inhibition of
acetate conversion into lipid in the liver and adipose tissue.43,89,90
The metabolic effects noted in these studies were not associated
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with any signiﬁcant change in energy intake,87,88 suggesting that
the positive effects on energy balance observed may be a result of
a change in energy utilisation and expenditure.
A recent study carried out by Remely et al.91 demonstrated a
lower methylation status in the promoter region of the FFA3 gene
in the blood of both obese and type 2 diabetics, when compared
with lean individuals. The researchers hypothesise that this is
owing to compositional differences in the gut microbiota and
therefore different SCFA proﬁles.
SCFAs, energy expenditure and substrate metabolism
Although the consumption of FCs and SCFAs have been
associated with a reduction in energy intake, there is also
evidence that SCFAs may increase energy expenditure. SCFAs
have been shown to increase the rates of oxygen consumption,
enhance both adaptive thermogenesis and fat oxidation and
increase mitochondrial function in rodents.73,92 Marsan and
McBurney93 also demonstrated that the oxidation of all three
principle SCFAs was signiﬁcantly higher for colonocytes isolated
from rodents who had consumed a high ﬁbre diet for 14 days. Gao
et al.73 also investigated the expression of two thermogenesis-
related genes, PGC-1α and UCP-1, and discovered that the mRNA
and expression of both genes were upregulated in those whose
diets were supplemented with butyrate. Furthermore, consuming
a diet high in whole-grain foods has been shown to decrease
urinary excretion of markers of protein catabolism which was
associated with an increase in SCFA production.94 In addition, it
has been demonstrated that SCFAs can be used as an energy
source for protein gain when pigs are fed below their energy
requirements.95
Evidence from several research studies indicates that the SCFA
receptors FFA2 and FFA3 may have a critical role in energy
homeostasis. It has been demonstrated that FFA3 KO mice exhibit
a reduced energy expenditure, compared with WT mice, despite
having matching physical activity levels.92,96 In addition, Kimura
et al.92 reported that treatment with propionate increases the rate
of oxygen consumption in WT mice, a result that was not present
in FFA3 KO mice. SCFAs were subsequently shown to stimulate
sympathetic nervous system activity directly through FFA3 at the
sympathetic ganglion, thereby controlling energy expenditure.92
In addition, recent evidence suggests that propionate binds FFA3
in the periportal afferent system to induce intestinal gluconeo-
genesis (IGN) via a gut–brain neural circuit.97 Similarly, it has been
reported that FFA2 KO mice exhibit a reduction in energy
expenditure when fed a high-fat diet, compared with WT mice,
and are obese despite a similar physical activity level.98 In contrast,
mice with adipose-speciﬁc overexpression of FFA2 exhibited an
increase in energy expenditure. Interestingly, the FFA2 KO mice
had a higher RER than WT mice, which suggests a reduced
capacity to oxidise fat, whereas mice with adipose-speciﬁc
overexpression of FFA2 had a lower RER than WT mice. The
authors note that their results indicate that FFA2 activation
increases energy expenditure and the capacity to oxidise fats via
the suppression of fat accumulation and adipose tissue insulin
signalling.
Research suggests that SCFAs and their receptors, FFA2 and
FFA3, may have a critical role in maintaining energy homeostasis.
However, there is currently no known study that has speciﬁcally
investigated the effect of FC consumption on energy expenditure
in humans and would make for an interesting line of investigation.
SCFAs and hepatic metabolism
There is evidence that feeding rodents a diet supplemented with
FCs or SCFAs results in reduced intrahepatocellular lipid levels,
liver triglyceride and cholesterol content, hepatic cholesterol
synthesis and hepatic glucose production.52,53,97,99–101 SCFAs are
absorbed from the intestinal lumen into the portal vein and
subsequently enter the hepatic blood ﬂow. As butyrate is the
preferred fuel for colonocytes, the majority of butyrate produced
in the gut is rapidly utilised at the epithelium.18,102 In contrast, the
majority of propionate and acetate produced in the gut is
absorbed and drains into the portal vein.103 Cummings et al.18
investigated SCFA distribution in sudden death victims and
demonstrated that the majority of butyrate and propionate
present in the portal vein is extracted by the liver and
subsequently metabolised (86 and 94%, respectively), with a
small amount of remaining propionate and butyrate entering
venous blood. Bloemen et al.102 reported that liver uptake of
acetate was not signiﬁcant. These results may suggest that any
hepatic changes associated with FC consumption or SCFA
administration are largely because of the metabolism of
propionate by the liver. It is known that propionate is
a gluconeogenic substrate and inhibits the utilisation of acetate
for lipid and cholesterol synthesis.89,104 Therefore, potential
upregulation of this pathway after FC consumption is likely to
be responsible for any observed changes in hepatic structure or
function.
A number of studies have reported that FC consumption in
humans beneﬁcially affects serum cholesterol and triglyceride
concentrations, and reduces hepatic lipogenesis.31,35,105–107
In addition, our research group recently demonstrated a
signiﬁcant reduction in the intrahepatocellular lipid levels of
overweight adults meeting the criteria for non-alcoholic fatty
liver disease after a 24-week increase in colonic propionate
concentrations.86 Furthermore, SCFAs may have an indirect
beneﬁt on hepatic metabolism through their effect on gut
hormone secretion. In particular, GLP-1 has been shown to
modulate physiological mechanisms responsible for free fatty acid
accumulation in the liver and reduce hepatic steatosis.108
SCFAs, glucose uptake and gluconeogenesis
The consumption of FCs has been associated with an improve-
ment in glucose homeostasis, although the evidence in humans is
inconsistent. Propionate is gluconeogenic and has been shown to
produce a dose-dependent increase in blood glucose concentra-
tions in humans.89,104,109 Again, the notion that FC consumption
may have beneﬁcial effects on glucose homeostasis appears
paradoxical. However, it has been demonstrated that SCFAs have
no signiﬁcant effect on glucose metabolism in healthy men.110
In addition, it has been shown that propionate-supplementation
induces a reduction in fasting blood glucose in rats.111
The intestine has recently been established as a gluconeogenic
organ and it has been reported that IGN promotes metabolic
beneﬁts and regulates energy and glucose homeostasis.112,113
Delaere et al.114 later demonstrated that a portal vein glucose sensor
is activated by IGN and transmits signals to the brain via the
peripheral nervous system, which initiates these beneﬁcial effects. It
has been reported that both propionate and butyrate stimulate
IGN.97 Although butyrate was found to directly activate the
expression of IGN genes in enterocytes, propionate itself was shown
to act as a substrate for IGN. In addition, rats fed a SCFA- or a FC-
supplemented diet displayed a signiﬁcantly lower weight gain,
reduced adiposity, improved glucose control and reduced hepatic
glucose production when compared with the control group. It was
noted that this improvement in glucose tolerance involved both gut–
brain communication and IGN, and that none of the reported
metabolic beneﬁts were present in mice lacking the catalytic subunit
of a key enzyme involved in IGN, intestinal glucose-6-phosphatase,
despite a similar shift in the gut microbiota composition. These data
suggest that IGN has a major role in mediating the beneﬁcial effects
associated with the consumption of FCs.
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SCFAs and adipocytes
It has been observed that FC consumption protects against fat
mass development.26–28 All three principle SCFAs have also been
shown to protect against diet-induced obesity.55
A number of studies have reported that treatment with the
SCFAs, propionate and acetate increases the expression of leptin, a
potent anorectic hormone, in adipocytes in vitro, whereas butyrate
has been shown to have no effect.43,45,46 In addition, propionate
has been shown to increase plasma leptin concentrations in mice
in vivo45 and stimulate mRNA expression in human adipose
tissue.115 Xiong et al.45 reported that this SCFA-stimulated increase
in leptin expression in adipocytes is mediated by FFA3. However,
not all reports regarding the body composition of FFA3 KO mice
have been consistent.55,68,96 Furthermore, a number of contra-
dictory reports suggesting that the expression of FFA3 cannot be
detected in adipose tissue have been published, indicating that
the SCFA-stimulated increase in leptin expression is not mediated
by FFA3.43,46 Zaibi et al.46 suggest that the SCFA-stimulated
increase in leptin expression is mediated by FFA2 and that the
downregulation of FFA2 in FFA3 KO mice is responsible for the
reduction in SCFA-stimulated leptin secretion observed in FFA3
KO mice. However, Frost et al.47 failed to demonstrate a signiﬁcant
effect of SCFAs on leptin secretion in adipocytes.
Kimura et al.98 recently demonstrated that SCFA-mediated
activation of FFA2 suppresses insulin signalling within adipocytes,
which results in the inhibition of fat accumulation within adipose
tissue and the promotion of metabolism of unincorporated
glucose and lipids in other tissues. In addition, it was reported
that FFA2 KO mice were obese on a normal diet, which was further
enhanced by a high-fat diet, that adipose-speciﬁc FFA2 transgenic
mice had a signiﬁcantly lower body weight than WT mice and that
mice overexpressing FFA2 in their adipose tissue remained lean
even when consuming a high-fat diet. The researchers suggest
that FFA2 may act as a sensor for excessive dietary energy,
controlling energy utilisation and maintaining metabolic home-
ostasis. However, these observations are not supported by Bjursell
et al.116 who reported that FFA2-deﬁcient mice consuming a high-
fat diet exhibit a reduction in body-fat mass and increase in lean
body mass. In addition, it has been shown that all three principle
SCFAs enhance the degree of adipocyte differentiation43,117 and
that propionate and acetate inhibit lipolysis.43 Hong et al.43 also
demonstrated that propionate increases the expression of FFA2
during adipocyte differentiation and causes an upregulation of
PPAR-γ2. The authors suggest that these results indicate the
involvement of FFA2 in the lipid accumulation pathway. This is
further supported by Ge et al.118 who reported that acetate and
propionate inhibit adipose tissue lipolysis in a mouse model via
FFA2 resulting in a reduction in plasma free fatty acid concentra-
tions. Hosseini et al.119 demonstrated that propionate increased
the gene expression of adiponectic receptors 1 and 2 in the
adiponectin system.
It has also been suggested that FFA3 may have a role in insulin-
stimulated glucose uptake. Han et al.120 reported that propionate
Figure 2. An overarching model for the beneﬁcial effects of colonic SCFA production on appetite regulation and energy homeostasis.
FCs, fermentable carbohydrates; FFA, free fatty acids; FFA2, free fatty acid receptor 2; FFA3, free fatty acid receptor 3; GLP-1, glucagon like
peptide-1; IGN, intestinal gluconeogenesis; PYY, peptide YY; SCFAs, short chain fatty acids; TG, triglyceride.
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and valerate enhance insulin-stimulated glucose uptake in
adipocytes which appeared to be mediated via FFA3.
Although data from animal studies suggest that SCFAs and the
activity of their receptors, FFA2 and FFA3, may have an inhibitory
effect against weight gain, there is currently a lack of evidence to
support this hypothesis in humans. As acetate and propionate are
the most potent activators of FFA2 it seems likely that these SCFAs
are responsible for any adipocyte-related changes observed after
FC consumption or SCFA administration. However, as acetate
circulates at a higher concentration than both butyrate and
propionate, it seems the most likely SCFA to directly inﬂuence
adipose tissue.18
CONCLUSION
A signiﬁcant body of evidence suggests that SCFAs have a
beneﬁcial role in appetite and energy homeostasis. However, as
the majority of research comes from animal models, caution when
translating this evidence to humans is necessary. Thus, there is an
urgent need for human data to support the mechanistic data
being reported. One major issue is that large amounts of FCs are
generally not tolerated well by humans, which results in a
relatively small amount of FCs being used in human experimental
diets when compared with animal studies. Therefore, effective
strategies that replicate the changes in SCFA proﬁles seen in
animal studies, either via dietary or pharmacological means, may
have the potential to translate the beneﬁcial effects observed in
animal studies to man.
In conclusion, it is evident that the administration of FCs and
their breakdown products, SCFAs, have positive effects on host
physiology. However, the majority of recent publications have
investigated the effect of SCFAs on one particular tissue or
metabolic process and have failed to look at the body system as
a whole. Here, we propose that SCFAs have a number of
metabolic processes, which are activated in parallel, that affect
energy homeostasis and appetite regulation (summarised in
Figure 2). Furthermore, the site-speciﬁc uptake of SCFA across
the gut–liver–peripheral tissue axis suggests selectivity in the
effect of individual SCFA. It is only by bringing these effects
together that the true impact of SCFAs on host energy
homeostasis can be seen.
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